Celcuity (CELC) Long-Term Investments (2017 - 2018)

Celcuity's (CELC) quarterly Long-Term Investments came in at $3.9 million in Q3 2018, down 43.59% on a QoQ basis from $6.9 million in Q2 2018.

Analysis

Celcuity (CELC) Long-Term Investments (2017 - 2018) Analysis & Trends

Celcuity (CELC) has 2 years of Long-Term Investments data on file, last reported at $3.9 million in Q3 2018.

Quarterly Long-Term Investments changed N/A year-over-year to $3.9 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $3.9 million (changed N/A YoY) and the FY2017 annual result came in at $7.2 million, changed N/A from the prior year.
Long-Term Investments eased to $3.9 million in Q3 2018, from $6.9 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $7.2 million in Q4 2017 to a low of $3.9 million in Q3 2018.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-4.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	1.77 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	22.17 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	372.10 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Celcuity	5.25 Bn	5.25 Bn	-	-

Historic Data

Download Data